SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor Corp is trending as investors digest a major partnership between AWS and Cerebras, with the market increasingly recognizing Vicor's role in providing the high-performance power delivery systems essential for Cerebras's AI hardware. Traders are actively monitoring the stock's high volatility and technical setups, while community sentiment remains split between excitement over Vicors AI data center exposure and caution regarding its valuation and recent price swings.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr is currently trending as community members weigh its potential as foundational Web3 infrastructure against intense frustration over its long-term price stagnation. While some investors emphasize the value of its bare-metal RPC network and upcoming Neura integration, others actively dismiss the project as a dormant, failed asset and frequently express extreme hostility toward the development team.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending as investors debate its long-term potential following a period of volatility and community speculation regarding upcoming institutional partnerships and infrastructure developments. The discourse remains highly polarized, with some community members aggressively accumulating on dips due to the project's high-throughput claims and strategic associations, while others express frustration over price performance and the heavy volume of social media promotion.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as the community debates the project's long-term potential amid significant price volatility and recent negative sentiment surrounding the ASI token migration. While some investors are aggressively accumulating at current levels, betting on the utility of decentralized AI agents and strategic partnerships, others are concerned about ongoing FUD and are waiting for clearer signs of a sustained trend reversal.

Invesco Capital Management LLC - PowerShares UltraShort Lehman 20+ Year Treasury ProShares 2x Shares

ProShares UltraShort 20+ Year Treasury ETF

The community is actively discussing a bond market selloff, with traders utilizing $TBT to hedge against rising long-term Treasury yields and potential stagflationary pressures. Investors are closely monitoring hawkish Fed rhetoric, deficit concerns, and increased debt issuance as primary catalysts for the ongoing volatility in the bond complex.

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Lipocine Inc

Lipocine is currently in focus as investors await critical Phase 3 topline results for its oral PPD treatment, LPCN 1154, expected early in April. While the community remains divided on the risks of pre-results dilution, discussions are heavily centered on the potential for this drug to disrupt the PPD market by offering a more convenient, home-based alternative to existing IV-based therapies.

Melco Resorts & Entertainment Ltd. engages in the management and development of casino gaming and entertainment resort facilities. The firm focuses on the administration of Mocha Clubs, Altira Macau, City of Dreams, Studio City, and City of Dreams Manila. It operates through the following geographical segments: Macau, the Philippines, Cyprus, and Corporate and Other. The company was founded by Yau Lung Ho in December 2004 and is headquartered in Hong Kong.

Melco Resorts & Entertainment Ltd - ADR

Melco Crown Entertainment Ltd.

Melco Resorts is seeing heightened activity as analysts debate its valuation amid broader Macau gaming sector recovery and persistent concerns over debt levels and market share. Community sentiment is mixed, with some traders optimistic about long-term potential following recent positive GGR data, while others express frustration over the stock's volatility and the operational headwinds in its non-Macau assets.

Match Group, Inc. engages in the provision of dating products worldwide. Its portfolio of brands includes Tinder, Match, Meetic, OkCupid, Hinge, Pairs, PlentyOfFish, and OurTime. The company was founded in 1995 and is headquartered in Dallas, TX.

Match Group Inc. - Ordinary Shares - New

Match Group Inc.

Match Group is drawing intense investor focus as activist pressures from firms like Starboard Value and Elliott Management mount, keeping the stock in a tight trading range while they push for operational improvements and potential value-unlocking strategies. The community remains deeply divided, with some traders betting on a turnaround driven by Hinge's growth and share buybacks, while others are frustrated by Tinder's declining user trends, ongoing litigation, and the company's struggle to find a fresh narrative in a competitive dating landscape.

VeChain, founded in 2015, is a sustainability-focused blockchain driving mass adoption of Web3. Its energy-efficient VeChainThor chain delivers fast, low-cost transactions, making blockchain accessible to millions worldwide. With partnerships including UFC, BCG, and Walmart, and over 2 million active users on VeBetter-powered apps, VeChain is proving real-world impact at scale.  In 2024, the VeChain Renaissance upgrade was launched, introducing Ethereum compatibility, dPoS consensus, and dynamic gas fees. It cut VTHO inflation and introduced StarGate NFT staking, where users lock VET to mint transferable NFTs that earn VTHO, can be delegated to validators, and serve as governance instruments. The upgrade also added new eco node tiers, lowering entry barriers while keeping rewards across higher staking levels.  By combining adoption, upgraded tokenomics, and inclusive staking, VeChain is positioning itself as a leading blockchain where usage, growth, and rewards fuel long-term value creation.

Vechain

VeChain (VET) is currently trending as holders weigh long-term utility-based catalysts like the upcoming Hayabusa upgrade and EU Digital Product Passport mandates against frustration over prolonged price stagnation. While community sentiment is heavily polarized between those accumulating at current lows and others expressing extreme pessimism over recent performance, active discussions remain focused on institutional partnerships and the potential for a long-awaited shift in network activity.

Tria is a self-custodial neobank and cross-chain payments infrastructure designed to make onchain money usable in everyday life. It combines card spending, trading, and earning in a single account experience, so users can move value across chains without manually bridging assets, switching networks, or managing chain-specific steps. Under the hood, Tria routes every action through BestPath, an ultra-fast routing and execution layer that takes an intent like “spend,” “swap,” “send,” or “earn” and completes it end-to-end on the optimal path. Tria operates in two modes: a consumer app that includes a Visa-powered card, spot swaps, perpetual futures, and Earn vaults, and a developer and institutional layer that integrates with protocols and ecosystems to embed Tria’s execution rails wherever value already moves. The end goal is simple: one continuous flow for money across chains, with self-custody by default and a product experience that feels effortless for normal users worldwide.

TRIA

TRIA is gaining momentum as investors track consistent growth in its self-custodial neobanking platform, driven by anticipation of upcoming major banking partnerships and exchange listings. Community members are actively highlighting the project's real-world financial metrics, such as futures volume and card spending, while speculating on the impact of future product announcements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research...

D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)

D. Boral Capital restated a "buy" rating and issued a $15.00 target price on shares of Coya Therapeutics in a research note on Monday...

Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Chardan Capital restated a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Monday...

Coya Therapeutics (NASDAQ:COYA) Announces Quarterly Earnings Results

Coya Therapeutics (NASDAQ:COYA - Get Free Report) issued its earnings results on Monday. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of...

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative...

Coya Therapeutics (COYA) to Release Quarterly Earnings on Tuesday

Coya Therapeutics (NASDAQ:COYA) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 17. (View Earnings Report at...

Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Recommendation of "Moderate Buy" by Brokerages

Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings...

Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?

Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital

D. Boral Capital restated a "buy" rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Wednesday...

Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

COYA
Coya Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest COYA News

COYACoya Therapeutics Inc